A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Amatuximab (Primary)
- Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01521325).
- 09 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov. (NCT01521325)